Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Timothy N. Trotter"'
Autor:
Timothy N. Trotter, Carina E. Dagotto, Delila Serra, Tao Wang, Xiao Yang, Chaitanya R. Acharya, Junping Wei, Gangjun Lei, H. Kim Lyerly, Zachary C. Hartman
Publikováno v:
JCI Insight, Vol 8, Iss 22 (2023)
Approximately 30% of breast cancer survivors deemed free of disease will experience locoregional or metastatic recurrence even up to 30 years after initial diagnosis, yet how residual/dormant tumor cells escape immunity elicited by the primary tumor
Externí odkaz:
https://doaj.org/article/d630aeef2f8e4adf98baca9e12652d01
Autor:
Li-Chung Tsao, Erika J. Crosby, Timothy N. Trotter, Junping Wei, Tao Wang, Xiao Yang, Amanda N. Summers, Gangjun Lei, Christopher A. Rabiola, Lewis A. Chodosh, William J. Muller, Herbert Kim Lyerly, Zachary C. Hartman
Publikováno v:
JCI Insight, Vol 7, Iss 6 (2022)
Two HER2-specific mAbs, trastuzumab and pertuzumab (T+P), combined with chemotherapy comprise standard-of-care treatment for advanced HER2+ breast cancers (BC). While this antibody combination is highly effective, its synergistic mechanism-of-action
Externí odkaz:
https://doaj.org/article/c87d5137315e42528a934056270a6891
Autor:
Yang Yang, Mohammad Q. Hassan, Xiaoxiao Hao, Xiaoxuan Xu, Timothy N. Trotter, Benjamin J. Wildman, Pramod S. Gowda
In multiple myeloma, abnormal plasma cells accumulate and proliferate in the bone marrow. Recently, we observed that Runx2, a bone-specific transcription factor, is highly expressed in multiple myeloma cells and is a major driver of multiple myeloma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17a1b0831d5b303155085c1da5cbb104
https://doi.org/10.1158/1541-7786.c.6540382.v1
https://doi.org/10.1158/1541-7786.c.6540382.v1
Autor:
Yang Yang, Mohammad Q. Hassan, Xiaoxiao Hao, Xiaoxuan Xu, Timothy N. Trotter, Benjamin J. Wildman, Pramod S. Gowda
Antibodies used for Western blotting and FACS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0012face04912e610aaefbefd58701cf
https://doi.org/10.1158/1541-7786.22512934
https://doi.org/10.1158/1541-7786.22512934
Autor:
Yang Yang, Juan Li, Joanne E. Murphy-Ullrich, Amjad Javed, Mark J. Suto, Yun Lu, Pramod S. Gowda, Timothy N. Trotter, Xiaoxuan Xu, Chao Zhang
Supplementary Figure S1-S6Supplementary Figure S1 shows tumor burden in the mice before BTZ treatment started (S1A), MM cell growth and apoptosis after co-cultured with BMS or pre-OBs of OB-Runx2-/- or OB-Runx2+/+ mice (S1B-F), and the proportion of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654071ef467ffa3d7788adaf05686976
https://doi.org/10.1158/1535-7163.22522383
https://doi.org/10.1158/1535-7163.22522383
Autor:
Yang Yang, Mohammad Q. Hassan, Xiaoxiao Hao, Xiaoxuan Xu, Timothy N. Trotter, Benjamin J. Wildman, Pramod S. Gowda
5TGM1 cells stably overexpressing miR-342 and miR-363 were established by lentiviral vector transduction.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27c2bc1ce7361afc52c0c0755fcce79a
https://doi.org/10.1158/1541-7786.22512949.v1
https://doi.org/10.1158/1541-7786.22512949.v1
Autor:
Yang Yang, Juan Li, Joanne E. Murphy-Ullrich, Amjad Javed, Mark J. Suto, Yun Lu, Pramod S. Gowda, Timothy N. Trotter, Xiaoxuan Xu, Chao Zhang
Supplementary Table S1Supplementary Table S1 shows the company's name and the product numbers of Bortezomib, 5-Fluorouracil and Gemcitabine as well as the company's name and the product numbers of all antibodies listed in table S1, which we purchased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95ec928c9116b274bba0cd33a3c8bec
https://doi.org/10.1158/1535-7163.22522374.v1
https://doi.org/10.1158/1535-7163.22522374.v1
Autor:
Yang Yang, Juan Li, Joanne E. Murphy-Ullrich, Amjad Javed, Mark J. Suto, Yun Lu, Pramod S. Gowda, Timothy N. Trotter, Xiaoxuan Xu, Chao Zhang
Multiple myeloma is a plasma cell malignancy that thrives in the bone marrow (BM). The proteasome inhibitor bortezomib is one of the most effective first-line chemotherapeutic drugs for multiple myeloma; however, 15% to 20% of high-risk patients do n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8039e3b38a33edb05a14d0cbf3928779
https://doi.org/10.1158/1535-7163.c.6543357.v1
https://doi.org/10.1158/1535-7163.c.6543357.v1
Autor:
Yang Yang, Juan Li, Joanne E. Murphy-Ullrich, Amjad Javed, Mark J. Suto, Yun Lu, Pramod S. Gowda, Timothy N. Trotter, Xiaoxuan Xu, Chao Zhang
Supplementary MethodsSupplementary Methods descript detailed methods of Bioluminescence imaging, ELISA, Flow cytometry, Isolation and culture of Pre-OBs with 5TGM1-Luc MM cells, Generation and sorting of MDSCs, Cell proliferation assays, Treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79d7885a8b9c35f6cab6cc0a136e03e5
https://doi.org/10.1158/1535-7163.22522380
https://doi.org/10.1158/1535-7163.22522380
Autor:
Yang Yang, Juan Li, Amjad Javed, Selvarangan Ponnazhagan, Yun Lu, Pramod S. Gowda, Timothy N. Trotter, Chao Zhang, Xiaoxuan Xu
The Supplementary Figures show the characterization of OB-Runx2 mouse model and the results of analysis of BM immunity after depletion of MDSCs by 5-FU.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::770b267a1a68e15e1758786e48c7359a
https://doi.org/10.1158/0008-5472.22426602
https://doi.org/10.1158/0008-5472.22426602